CELC

Celcuity Inc

Add to Watchlist

Advanced Chart

13.780

-0.27(-1.922%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

14.080

Open

14.080

VWAP

13.87

Vol

48.53K

Mkt Cap

532.02M

Low

13.590

Amount

673.37K

EV/EBITDA(TTM)

Total Shares

35.10M

424.86M

EV/OCF(TTM)

P/S(TTM)

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

7 Analyst Rating

105.01% Upside

Wall Street analysts forecast CELC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is 28.25 USD with a low forecast of 27.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

105.01% Upside

Current: 13.780

Low

27.00

Averages

28.25

High

30.00

105.01% Upside

Current: 13.780

Low

27.00

Averages

28.25

High

30.00

Stifel

initiated

$30

2025-07-01

Reason

Stifel

Price Target

$30

2025-07-01

initiated

Reason

Stifel resumed coverage of Celcuity with a Buy rating and $30 price target. Stifel views gedatolisib as a uniquely differentiated asset poised to emerge as a standard-of-care treatment option within an increasingly competitive 2L+ HR+/HER2- metastatic breast cancer development landscape and thinks preclinical data clearly establishes gedatolisib's enhanced potency vs. single-node PI3K/AKT/mTOR signaling pathway inhibitors, the analyst tells investors in a research note. The firm believes Q3 topline VIKTORIA-1 mPFS data in PIK3CA-wild-type patients represents favorable risk/reward at current valuation

Needham

Gil Blum

Strong Buy

Reiterates

$29

2025-04-11

Reason

Needham

Gil Blum

Price Target

$29

2025-04-11

Reiterates

Strong Buy

Reason

Needham

Gil Blum

Strong Buy

Reiterates

$29

2025-04-01

Reason

Needham

Gil Blum

Price Target

$29

2025-04-01

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$27

2025-04-01

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$27

2025-04-01

Reiterates

Strong Buy

Reason

Needham

Gil Blum

Strong Buy

Maintains

$23 → $29

2025-02-06

Reason

Needham

Gil Blum

Price Target

$23 → $29

2025-02-06

Maintains

Strong Buy

Reason

Needham

Gil Blum

Strong Buy

Reiterates

$23

2024-11-15

Reason

Needham

Gil Blum

Price Target

$23

2024-11-15

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Celcuity Inc (CELC.O) is -4.12, compared to its 5-year average forward P/E of -6.22. For a more detailed relative valuation and DCF analysis to assess Celcuity Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.22

Current PE

-4.12

Overvalued PE

-2.58

Undervalued PE

-9.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.29

Current EV/EBITDA

-2.63

Overvalued EV/EBITDA

0.19

Undervalued EV/EBITDA

-2.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

82.72

Current PS

0.00

Overvalued PS

351.46

Undervalued PS

-186.02